CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
September 26, 2023 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
September 08, 2023 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
September 06, 2023 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath
August 30, 2023 08:00 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
August 08, 2023 07:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023
July 26, 2023 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants
June 28, 2023 22:57 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 28, 2023 16:07 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
June 21, 2023 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections
June 15, 2023 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J. , June 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...